Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823745 · ClinicalTrials.gov registry record · Phase 1
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00823745 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 7 participants.
The verdict
NCT00823745, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a phase 1 study to assess the routes of elimination of a single oral dose of \[14C\] PF-00868554 and to characterize the metabolic profile following single dose administration.
Interventions
- DRUG [14C]-PF-00868554
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823745
The ClinicalTrials.gov registry entry for NCT00823745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-PF-00868554 is the first listed.
NCT00823745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823745 about?
NCT00823745 is a clinical study titled "Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects". This is a phase 1 study to assess the routes of elimination of a single oral dose of \[14C\] PF-00868554 and to characterize the metabolic profile following single dose administration.
What is the current status of trial NCT00823745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00823745?
The interventions under investigation include: [14C]-PF-00868554 (DRUG).
Who is sponsoring clinical trial NCT00823745?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.